Rigel to Present at the Jefferies London Healthcare Conference
Rigel Pharmaceuticals (Nasdaq: RIGL) has announced that CFO Dean Schorno will present a company overview at the Jefferies London Healthcare Conference on Tuesday, November 19, at 9:30 am GMT (4:30 am EST). The presentation will be accessible via live webcast through the Investor Relations section of Rigel's website.
Founded in 1996 and based in South San Francisco, Rigel is a commercial stage biotechnology company focusing on developing therapies for hematologic disorders and cancer. The company aims to discover, develop, and provide novel treatments that improve patients' lives.
Rigel Pharmaceuticals (Nasdaq: RIGL) ha annunciato che il CFO Dean Schorno presenterà una panoramica dell'azienda alla Jefferies London Healthcare Conference martedì 19 novembre alle 9:30 GMT (4:30 EST). La presentazione sarà accessibile tramite webcast dal vivo nella sezione Relazioni con gli Investitori del sito web di Rigel.
Fondata nel 1996 e con sede a South San Francisco, Rigel è una azienda biotecnologica in fase commerciale che si concentra sullo sviluppo di terapie per disturbi ematologici e cancro. L'azienda si propone di scoprire, sviluppare e fornire nuovi trattamenti che migliorano la vita dei pazienti.
Rigel Pharmaceuticals (Nasdaq: RIGL) ha anunciado que el CFO Dean Schorno presentará una visión general de la empresa en la Jefferies London Healthcare Conference el martes 19 de noviembre a las 9:30 am GMT (4:30 am EST). La presentación será accesible a través de una transmisión en vivo a través de la sección de Relaciones con los Inversores en el sitio web de Rigel.
Fundada en 1996 y con sede en South San Francisco, Rigel es una empresa de biotecnología en etapa comercial que se centra en desarrollar terapias para trastornos hematológicos y cáncer. La empresa tiene como objetivo descubrir, desarrollar y proporcionar tratamientos novedosos que mejoren la vida de los pacientes.
리겔 제약 (Nasdaq: RIGL)이 CFO 딘 쇼르노가 제퍼리 런던 헬스케어 컨퍼런스에서 회사 개요를 발표할 것이라고 발표했습니다. 발표는 11월 19일 화요일 GMT 오전 9시 30분 (EST 오전 4시 30분)에 있을 예정입니다. 발표는 리겔 웹사이트의 투자자 관계 섹션을 통해 실시간 웹캐스트로 접근할 수 있습니다.
1996년에 설립되고 남샌프란시스코에 본사를 둔 리겔은 상업 단계의 생명공학 회사로, 혈액 질환 및 암 치료제 개발에 주력하고 있습니다. 이 회사는 환자의 삶을 개선하는 새로운 치료법을 발견하고 개발하며 제공하는 것을 목표로 하고 있습니다.
Rigel Pharmaceuticals (Nasdaq: RIGL) a annoncé que le CFO Dean Schorno présentera un aperçu de l'entreprise lors de la Jefferies London Healthcare Conference le mardi 19 novembre à 9h30 GMT (4h30 EST). La présentation sera accessible par webcast en direct à travers la section Relations Investisseurs du site Web de Rigel.
Fondée en 1996 et basée à South San Francisco, Rigel est une entreprise de biotechnologie en phase commerciale qui se concentre sur le développement de thérapies pour les troubles hématologiques et le cancer. L'objectif de l'entreprise est de découvrir, développer et fournir des traitements novateurs qui améliorent la vie des patients.
Rigel Pharmaceuticals (Nasdaq: RIGL) hat angekündigt, dass CFO Dean Schorno eine Unternehmensübersicht auf der Jefferies London Healthcare Conference am Dienstag, den 19. November um 9:30 Uhr GMT (4:30 Uhr EST) präsentieren wird. Die Präsentation wird über einen Live-Webcast im Bereich Investor Relations auf der Website von Rigel zugänglich sein.
Gegründet im Jahr 1996 und mit Sitz in South San Francisco, ist Rigel ein biotechnologisches Unternehmen in der Kommerzialisierungsphase, das sich auf die Entwicklung von Therapien für hämatologische Erkrankungen und Krebs konzentriert. Das Unternehmen hat das Ziel, neuartige Behandlungen zu entdecken, zu entwickeln und anzubieten, die das Leben der Patienten verbessern.
- None.
- None.
To access the live webcast or archived recording, visit the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website prior to the start of the live webcast to allow for any software downloads.
About Rigel
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in
Contact for Investors & Media:
Investors:
Rigel Pharmaceuticals, Inc.
650.624.1232
ir@rigel.com
Media:
David Rosen
Argot Partners
646.461.6387
david.rosen@argotpartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-to-present-at-the-jefferies-london-healthcare-conference-302302060.html
SOURCE Rigel Pharmaceuticals, Inc.
FAQ
When is Rigel Pharmaceuticals (RIGL) presenting at the Jefferies London Healthcare Conference?
Who will represent RIGL at the Jefferies London Healthcare Conference?
How can investors access RIGL's presentation at the Jefferies Conference?
What is Rigel Pharmaceuticals' (RIGL) main business focus?
